Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rezvilutamide plus ADT as neoadjuvant therapy for locally advanced prostate cancer
ChiCTR2500106983Phase 4Not yet recruiting
- Sponsor
- Xijing Hospital
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of rezvilutamide in prostate adenocarcinoma, sponsored by Xijing Hospital. Primary endpoints: Pathological complete response rate (pCR) and Positive surgical margin rate (PSM). Planned start Aug 2025; status: not yet recruiting.
02
Drugs
rezvilutamide
03
Conditions
prostate adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2500106983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500106983.